Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: GPER1

Gene summary for GPER1

Gene summary.

Gene information	Species	Human
	Gene symbol	GPER1
	Gene ID	2852
	Gene name	G protein-coupled estrogen receptor 1
	Gene Alias	CEPR
	Cytomap	7p22.3
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	A0A024R849

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2852	GPER1	HCC1_Meng	Human	Liver	HCC	8.35e-06	3.42e-02	0.0246
2852	GPER1	HCC1	Human	Liver	HCC	9.63e-03	2.08e+00	0.5336
2852	GPER1	S014	Human	Liver	HCC	4.90e-16	5.99e-01	0.2254
2852	GPER1	S015	Human	Liver	HCC	3.00e-15	6.68e-01	0.2375
2852	GPER1	S016	Human	Liver	HCC	2.66e-25	7.88e-01	0.2243

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190382922	Liver	HCC	positive regulation of cellular protein localization	199/7958	276/18723	1.15e-23	2.62e-21	199
GO:002241112	Liver	HCC	cellular component disassembly	282/7958	443/18723	1.02e-19	1.38e-17	282
GO:190495122	Liver	HCC	positive regulation of establishment of protein localization	207/7958	319/18723	3.95e-16	3.29e-14	207
GO:200123322	Liver	HCC	regulation of apoptotic signaling pathway	226/7958	356/18723	7.26e-16	5.68e-14	226
GO:004586222	Liver	HCC	positive regulation of proteolysis	232/7958	372/18723	5.66e-15	3.98e-13	232
GO:005122222	Liver	HCC	positive regulation of protein transport	194/7958	303/18723	2.41e-14	1.56e-12	194
GO:003052222	Liver	HCC	intracellular receptor signaling pathway	171/7958	265/18723	3.00e-13	1.61e-11	171
GO:004343422	Liver	HCC	response to peptide hormone	247/7958	414/18723	9.55e-13	4.77e-11	247
GO:004854522	Liver	HCC	response to steroid hormone	206/7958	339/18723	6.81e-12	2.92e-10	206
GO:009719122	Liver	HCC	extrinsic apoptotic signaling pathway	143/7958	219/18723	6.99e-12	2.97e-10	143
GO:007265921	Liver	HCC	protein localization to plasma membrane	177/7958	284/18723	1.02e-11	4.18e-10	177
GO:007137521	Liver	HCC	cellular response to peptide hormone stimulus	179/7958	290/18723	2.54e-11	9.88e-10	179
GO:199077821	Liver	HCC	protein localization to cell periphery	200/7958	333/18723	6.07e-11	2.23e-09	200
GO:000606621	Liver	HCC	alcohol metabolic process	208/7958	353/18723	2.80e-10	9.50e-09	208
GO:190165321	Liver	HCC	cellular response to peptide	211/7958	359/18723	2.86e-10	9.63e-09	211
GO:190547511	Liver	HCC	regulation of protein localization to membrane	113/7958	175/18723	2.90e-09	7.78e-08	113
GO:001082112	Liver	HCC	regulation of mitochondrion organization	96/7958	144/18723	3.82e-09	1.02e-07	96
GO:007138322	Liver	HCC	cellular response to steroid hormone stimulus	128/7958	204/18723	3.92e-09	1.04e-07	128
GO:200123621	Liver	HCC	regulation of extrinsic apoptotic signaling pathway	98/7958	151/18723	2.17e-08	5.08e-07	98
GO:190437521	Liver	HCC	regulation of protein localization to cell periphery	83/7958	125/18723	5.60e-08	1.19e-06	83

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa01522	Liver	HCC	Endocrine resistance	58/4020	98/8465	1.28e-02	3.19e-02	1.78e-02	58
hsa015221	Liver	HCC	Endocrine resistance	58/4020	98/8465	1.28e-02	3.19e-02	1.78e-02	58

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

GPER1

SNV

Missense_Mutation

c.704N>T

p.Ser235Phe

p.S235F

Q99527

protein_coding

deleterious(0.03)

probably_damaging(0.98)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GPER1

SNV

Missense_Mutation

c.385N>A

p.Leu129Met

p.L129M

Q99527

protein_coding

tolerated(0.09)

probably_damaging(0.979)

TCGA-BH-A1F0-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GPER1

SNV

Missense_Mutation

novel

c.1061N>G

p.Ala354Gly

p.A354G

Q99527

protein_coding

tolerated_low_confidence(0.07)

benign(0.212)

TCGA-D8-A147-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine

GPER1

SNV

Missense_Mutation

rs199736734

c.652N>C

p.Glu218Gln

p.E218Q

Q99527

protein_coding

deleterious(0.01)

probably_damaging(1)

TCGA-LL-A440-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

GPER1

SNV

Missense_Mutation

c.140G>T

p.Gly47Val

p.G47V

Q99527

protein_coding

tolerated(0.14)

benign(0.039)

TCGA-EK-A2RB-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

GPER1

SNV

Missense_Mutation

rs201954771

c.88G>A

p.Glu30Lys

p.E30K

Q99527

protein_coding

tolerated_low_confidence(0.31)

benign(0.017)

TCGA-FU-A3HZ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

GPER1

SNV

Missense_Mutation

rs779447108

c.56N>T

p.Ala19Val

p.A19V

Q99527

protein_coding

tolerated_low_confidence(0.97)

benign(0)

TCGA-5M-AAT6-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Unknown

GPER1

SNV

Missense_Mutation

rs775750584

c.742N>T

p.Arg248Cys

p.R248C

Q99527

protein_coding

deleterious(0)

probably_damaging(0.959)

TCGA-AA-3673-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

GPER1

SNV

Missense_Mutation

novel

c.490N>T

p.Arg164Cys

p.R164C

Q99527

protein_coding

deleterious(0.02)

probably_damaging(0.939)

TCGA-AZ-4315-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

GPER1

SNV

Missense_Mutation

c.252N>A

p.Asn84Lys

p.N84K

Q99527

protein_coding

deleterious(0.04)

probably_damaging(0.999)

TCGA-CK-4951-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	antagonist	178103094
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	agonist	135650883	RALOXIFENE
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	agonist	135650294
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	antagonist	178100354
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	agonist	135651381
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	agonist	135651382
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	agonist	135650370	FULVESTRANT
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR		ESTRADIOL	ESTRADIOL	16520733
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR		Segesterone acetate and ethinyl estradiol vaginal system
2852	GPER1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR	agonist	135649800	AFIMOXIFENE

Page: 1 2